Davos Alzheimer's Collaborative

Healthcare system preparedness - dac is investing to transform the way healthcare systems worldwide detect, diagnose and treat alzheimer's. The goal is to take advantage of future innovations to improve the quality of life for people everywhere. In 2022, dac continued to advance 7 flagship projects in 6 countries as well as support and monitor the execution of the initial grants program (12 grants in total).

Global clinical trials - dac is building a global network of clinical trial sites and a supporting technology platform to reduce the cost and time of bringing new treatments to market. Dac developed a network of more than 30 european sites organized for accelerating studies and implementing novel trial designs and secured a pharmaceutical company sponsor.

Global cohorts - dac is building global cohorts to advance understanding of Alzheimer's among diverse populations. This data will provide the foundation for identifying new biomarkers and developing targeted treatments that work for people worldwide. In 2022, dac recruited 23 cohorts around the globe. As a basis to begin contracting, dac also executed a memorandum of understanding (mou) with a cohort managed by aga khan university in nairobi, kenya. Outreach to cohorts were targeted that have the strongest alignment with the scientific plan and access to the targeted measurements. Also in 2022, dac provided a letter of intent to the national institutes on health outlining a 5-year, $50m usd grant that was positively reviewed.